



ASX / Media Release  
24 October 2022

## September Appendix 4C & Investor Conference Call Details

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure, today advises that its Appendix 4C Cash Flow Report and Management Quarterly Activities Report for the three months ended 30 September 2022, will be released on Thursday, 27 October 2022.

The Company will host an investor conference call at 12.00pm AEDT on Thursday, 27 October 2022 with Dr Thomas Duthy, Executive Director.

Details of the call are set out below.

In order to pre-register for the conference call and avoid a queue when calling, please follow the link below. You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event.

<https://s1.c-conf.com/diamondpass/10026404-hg6fg5.html>

Alternatively, you may dial in with the following details, approximately five minutes before the scheduled start time and provide the Conference ID to an operator.

Conference ID: **10026404**

Participant Dial-in Numbers:

Australia Toll Free: 1800 908299  
Australia Local: +61 2 9007 8048  
New Zealand: 0800 452 795  
Canada/USA: 1855 624 0077  
Hong Kong: 800 968 273  
Japan: 006 633 868 000  
China: 108 001 401 776  
Singapore: 800 101 2702  
United Kingdom: 0800 0511 453

- ENDS -

***This release dated 24 October 2022 has been authorised for lodgement to ASX by Executive Director Tom Duthy of Invex Therapeutics.***

---

**For more information, please contact:**

**Company/Investors**

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

**Media**

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter @InvexThera\_ASX

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).